GSBR-1290 (Capsule/Tablet) + GSBR-1290 + Placebo + Placebo (Capsule/Tablet)
Phase 1UNKNOWN 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Healthy Volunteers
Conditions
Healthy Volunteers
Trial Timeline
Oct 2, 2023 → Mar 1, 2024
NCT ID
NCT06139055About GSBR-1290 (Capsule/Tablet) + GSBR-1290 + Placebo + Placebo (Capsule/Tablet)
GSBR-1290 (Capsule/Tablet) + GSBR-1290 + Placebo + Placebo (Capsule/Tablet) is a phase 1 stage product being developed by Structure Therapeutics for Healthy Volunteers. The current trial status is unknown. This product is registered under clinical trial identifier NCT06139055. Target conditions include Healthy Volunteers.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06139055 | Phase 1 | UNKNOWN |
Competing Products
20 competing products in Healthy Volunteers
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0837 | AstraZeneca | Phase 1 | 33 |
| Valsartan | Novartis | Phase 1 | 33 |
| CSL112 + Placebo | CSL | Phase 1 | 32 |
| UT-15C | United Therapeutics | Phase 1 | 30 |
| VNA-318 + Placebo | Biotrial | Phase 1 | 25 |
| Open-label TRV734 125 mg + TRV734 blinded + Oxycodone IR 10 mg + Placebo | Trevena | Phase 1 | 25 |
| TRV130 + Moxifloxacin + Placebo | Trevena | Phase 1 | 25 |
| Radiolabeled TRV130 | Trevena | Phase 1 | 25 |
| TRV130A + Dextrose in Water | Trevena | Phase 1 | 25 |
| TRV734 | Trevena | Phase 1 | 25 |
| ALT02 + EU-licensed Herceptin + US-licensed Herceptin | Alteogen | Phase 1 | 33 |
| ENZ215 + EU Sourced Prolia + US Sourced Prolia | Alkem Laboratories | Phase 1 | 33 |
| KPL-404 | Kiniksa Pharmaceuticals | Phase 1 | 28 |
| MORF-057 + Placebo for MORF-057 | Eli Lilly | Phase 1 | 33 |
| Propranolol + Pseudoephedrine | Eli Lilly | Pre-clinical | 23 |
| LY2157299 | Eli Lilly | Phase 1 | 33 |
| Lasmiditan + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3015014 + Placebo | Eli Lilly | Phase 1 | 33 |
| LOXO-783 | Eli Lilly | Phase 1 | 33 |
| LY2541546 - IV + LY2541546 - SC + Placebo | Eli Lilly | Phase 1 | 33 |
Other Products from Structure Therapeutics
aleniglipron or placebo + aleniglipron or placebo + aleniglipron or placebo + aleniglipron or placeboPhase 2
47
aleniglipron or placeboPhase 2
47
Aleniglipron or Placebo + Aleniglipron or Placebo + Aleniglipron or Placebo + Aleniglipron + Aleniglipron + Aleniglipron + AleniglipronPhase 2
47
Aleniglipron + PlaceboPhase 2
47
GSBR-1290 + PlaceboPhase 1/2
36